Company Will Leverage Holman’s Deep Sales and Marketing Experience for Commercialization of its Traumatic Brain Injury and Concussion Assessment Technology
BETHESDA, MD - July 21, 2016 – BrainScope Company, Inc., a privately held neurotechnology company focusing on traumatic brain injury (TBI) and concussion assessment, announced today the appointment of Andrew Holman as Chief Commercial Officer. With over 20 years’ experience in sales and marketing in top echelon medical device companies, Holman will lead the commercialization efforts for BrainScope as it approaches the anticipated launch of its first product.
Holman most recently served as President of Corporate Development for Greatbatch, Inc., with prior roles as Chief Commercial Officer and Executive Vice President of Global Sales and Marketing. During Holman’s tenure, Greatbatch exceeded market growth and completed a successful merger with Lake Region Medical, creating the largest medical device outsourcing organization in the world, now known as Integer Holdings Corporation.
Prior to joining Greatbatch, Holman served as Executive Vice President of U.S. Commercial Businesses at DJO Global, a leading worldwide provider of medical technologies that address the continuum of patient care from injury prevention to rehabilitation. At DJO Global, Holman helped drive the U.S. business from $800 million to well over $1 billion in sales in two years. This role provided him invaluable experience selling beyond hospital environments into the sports and physician markets. Holman previously served for four years as President of the Americas for Smith & Nephew Orthopaedics, during which time they were the fastest growing reconstructive joint company in the U.S. These accomplishments were paved by successful sales and marketing leadership positions at Boston Scientific Corporation and Johnson & Johnson. Andrew has also served on the Board of ThinkFirst, a non-profit organization whose mission is to prevent brain, spinal cord and other traumatic injuries through education, research and advocacy.
“We are delighted to welcome Andrew to the BrainScope team. This is a key hire for BrainScope as we prepare to bring our first product to market. Andrew has extensive experience in the key focus areas of medical device sales, strategic marketing and planning, business development, pricing and reimbursement. He has been highly successful in building high-performing commercial sales and marketing teams, both domestically and internationally. His well-rounded experience and enthusiasm makes him the perfect person to take us to the next level,” said Michael Singer, Chief Executive Officer of BrainScope.
“I am thrilled and honored to join the BrainScope organization and serve in this critical role. I am very impressed with the company's leadership and vision. I have a passion for traumatic brain injury and diseases of the central nervous system ever since my years at Johnson & Johnson, and believe that BrainScope is exceptionally well positioned to leverage its technological innovation in becoming the new standard of care in the assessment of TBI,” stated Holman.
BrainScope’s disruptive medical technology will change the way head-injured patients are assessed and managed, providing clinicians – for the first time – a comprehensive, objective and accessible view of a person’s head trauma. BrainScope’s technology can be used anywhere – whether in a locker room, at a military training site or battlefield, or an emergency room, urgent care center, or doctor’s office – giving clinicians an objective analysis in real time to inform an accurate diagnosis. The company’s technology is on track to be the first fully FDA-cleared, integrated and objective system used to immediately and objectively assess patients for the full spectrum of TBI.
BrainScope is a medical neurotechnology company that is developing a new generation of handheld, easy-to-use, non-invasive instruments designed to aid medical professionals in rapidly and objectively assessing various neurological conditions, starting with traumatic brain injury including concussion. The company has completed 21 clinical studies at 55 locations, with its technology featured in 15 peer-reviewed articles in leading scientific and medical publications. BrainScope has been awarded more than $27 million of U.S. Department of Defense research contracts for the development of its TBI and concussion assessment technology and was named both an original recipient and final awardee GE-NFL Head Health Challenge I. BrainScope has also received significant funding from private investors to accelerate its development efforts, with backing from Revolution (created by AOL co-founder Steve Case), Shaman Ventures, ZG Ventures, State of Maryland Venture Fund, Brain Trust Accelerator Fund, and Difference Capital. BrainScope devices in development are based on a proprietary technology platform, which integrates databases of over 7,000 brainwave recordings with advanced digital signal processing, sophisticated algorithms, miniaturized hardware and disposable headset sensors, which are all covered by an intellectual property portfolio of 100 issued and pending patents. In May 2015 the United States Food and Drug Administration (FDA) cleared the company’s Ahead 200 device, which uses commercial smartphone hardware leveraging Google’s Android operating system and a custom sensor to record and analyze a patient’s electroencephalogram (EEG) after head injury. BrainScope devices under development, including the Ahead 300 and the Ahead Concussion Assessment System, for assessment of traumatic brain injury and concussion are for investigational use only. For more information, please visit www.brainscope.com.